Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS
September 9th 2023Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.
Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma
September 8th 2023Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.
Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL
The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care
Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Ongoing Clinical Trials in the Metastatic CRPC Setting
Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.
Camidge and Vokes Reflect on Research Journeys, Team Building, and Mentorship
August 24th 2023In this episode of "How This Is Building Me," Drs Camidge and Vokes discuss the span of countries and institutions along Dr Vokes’ journey to MD Anderson Cancer Center, how Dr Vokes balances research and work in the clinic, and how the correct mentors can help shape career paths in oncology.
Potential for CDK4/6 Inhibitors in Metastatic CRPC
Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.
Novel Therapeutic Targets in Metastatic CRPC
A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.
Dr Masarova on the Investigation of Ropeginterferon Alfa in Essential Thrombocythemia
August 15th 2023Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.